CIRM grants delayed

The governing board of the California stem cell agency is delaying $58 million in new grants until March to wait out the poor economy and credit market. The linkurl:California Institute for Regenerative Medicine;http://www.cirm.ca.gov/ was created in 2004 with $3 billion in borrowing power to push stem cell research forward in the state. Since then, it has awarded almost $700 million in research and training grants to universities, institutes and research companies. On Friday, CIRM's board mem

Written byElie Dolgin
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
The governing board of the California stem cell agency is delaying $58 million in new grants until March to wait out the poor economy and credit market. The linkurl:California Institute for Regenerative Medicine;http://www.cirm.ca.gov/ was created in 2004 with $3 billion in borrowing power to push stem cell research forward in the state. Since then, it has awarded almost $700 million in research and training grants to universities, institutes and research companies. On Friday, CIRM's board members tentatively earmarked an additional $58 million for training researchers at six San Francisco-area institutions including Stanford University, the University of California, San Francisco, and UC Berkeley. But citing weaknesses in the bond market,
the board opted to reassess the situation in March before financing the new projects. The board has enough cash to support existing grant commitments through September, according to the__ linkurl:San Francisco Chronicle.;http://www.sfgate.com/cgi-bin/article.cgi?f=/c/a/2009/01/31/BA6A15KI27.DTL
**Related stories:__***linkurl:CIRM cuts ten grants;http://www.the-scientist.com/blog/display/53978/
[7th December 2007]*linkurl:Calif. court okays stem cell funding;http://www.the-scientist.com/news/display/53199/
[17th May 2007]*linkurl:California stem cell plans stalled, but alive;http://www.the-scientist.com/news/display/23097/
[8th February 2006]
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies